InvestorsHub Logo

H2R

Followers 42
Posts 2146
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: north40000 post# 1403

Friday, 12/02/2016 1:04:07 AM

Friday, December 02, 2016 1:04:07 AM

Post# of 1569
Wrong article. Below is the one I was thinking about:

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32049-9/fulltext?rss=yes


Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

Prof John R Teerlink, MDcorrespondencePress enter key for correspondence informationemailPress enter key to Email the author, Prof G Michael Felker, MD, Prof John J V McMurray, MD, Prof Scott D Solomon, MD, Kirkwood F Adams Jr, MD, Prof John G F Cleland, MD, Justin A Ezekowitz, MBBCh, Prof Assen Goudev, MD, Prof Peter Macdonald, MD, Prof Marco Metra, MD, Prof Veselin Mitrovic, MD, Prof Piotr Ponikowski, MD, Prof Pranas Serpytis, MD, Prof Jindrich Spinar, MD, Prof János Tomcsányi, MD, Hans J Vandekerckhove, MD, Prof Adriaan A Voors, MD, Maria Laura Monsalvo, MD, James Johnston, PhD, Fady I Malik, MD, Narimon Honarpour, MD for the COSMIC-HF Investigators
Published: 30 November 2016
Article has an altmetric score of 5
DOI: dx.doi.org/10.1016/S0140-6736(16)32049-9 |
showArticle Info
Summary
Full Text

Tables and Figures
References
Supplementary Material
Summary
Background
Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and effects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil.

Methods
In this randomised, double-blind study, done at 87 sites in 13 countries, we recruited patients with stable, symptomatic chronic heart failure and left ventricular ejection fraction 40% or lower. Patients were randomly assigned equally, via an interactive web response system, to receive 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group), 25 mg twice daily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or placebo for 20 weeks. We assessed the maximum concentration of omecamtiv mecarbil in plasma (primary endpoint) and changes in cardiac function and ventricular diameters. This trial is registered with ClinicalTrials.gov, number NCT01786512.

Findings
From March 17, 2014, to March 5, 2015, we enrolled 150 patients in the fixed-dose omecamtiv mecarbil group and 149 in the pharmacokinetic-titration and placebo groups. Mean maximum concentration of omecamtiv mecarbil at 12 weeks was 200 (SD 71) ng/mL in the fixed-dose group and 318 (129) ng/mL in the pharmacokinetic-titration group. For the pharmacokinetic-titration group versus placebo group at 20 weeks, least square mean differences were as follows: systolic ejection time 25 ms (95% CI 18–32, p<0·0001), stroke volume 3·6 mL (0·5–6·7, p=0·0217), left ventricular end-systolic diameter -1·8 mm (-2·9 to -0·6, p=0·0027), left ventricular end-diastolic diameter -1·3 mm, (-2·3 to 0·3, p=0·0128), heart rate -3·0 beats per min (-5·1 to -0·8, p=0·0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970 pg/mL (-1672 to -268, p=0·0069). The frequency of adverse clinical events did not differ between groups.

Interpretation
Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter.

Funding
Amgen.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYTK News